Deutsche Bank Aktiengesellschaft Reaffirms Sell Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reiterated by equities researchers at Deutsche Bank Aktiengesellschaft in a research report issued on Friday,Digital Look reports. They presently have a £115 target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential downside of 19.42% from the company’s previous close.

AZN has been the topic of a number of other research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a £180 target price on shares of AstraZeneca in a report on Friday. Citigroup upped their price target on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a report on Friday, April 10th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of £153.33.

AstraZeneca Stock Performance

AZN stock traded up GBX 210 during midday trading on Friday, hitting £142.72. 50,969,355 shares of the company traded hands, compared to its average volume of 35,587,070. AstraZeneca has a twelve month low of £101.03 and a twelve month high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66. The business has a 50 day simple moving average of £138.04 and a 200-day simple moving average of £141.13. The stock has a market capitalization of £221.34 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.